v3.25.4
Segment Reporting
 12 Months Ended
Dec. 31, 2025
Segment Reporting [Abstract]  
SEGMENT REPORTING

9 — SEGMENT REPORTING

 

The Company has one reportable operating segment relating to drug development for addiction and related disorders. When evaluating the Company’s financial performance, the Chief Operating Decision Maker (“CODM”) reviews total operating expenses for the operating segment excluding equity method investments. The CODM makes decisions using this information on a company-wide basis.

 

Significant segment expenses, as provided to the CODM, are presented below: 

 

   For the Years Ended
December 31,		 
   2025   2024 
Operating Expenses:        
Segment research and development $2,619,671  $3,229,226 
Segment general and administrative  5,179,791   5,055,231 
Total Operating Expenses  7,799,462   8,284,457 
Loss From Operations  (7,799,462)  (8,284,457)
Other Income (Expense)          
Interest income  149,567   178,659 
Inducement expense  —   (4,464,427)
Loss on equity method investment  (492,130)  (552,183)
Other income (expense)  164,854   (75,043)
Total other Income (Expense)  (177,709)  (4,912,994)
Net Loss $(7,977,171) $(13,197,451)